US 12,312,340 B2
Potent ASGPR-binding compounds for the degradation of immunoglobulins and other proteins
Jason Allan Wiles, Madison, CT (US); Srinivasa Karra, Pembrooke, MA (US); Mark George Saulnier, Higganum, CT (US); Jesse Jingyang Chen, Lexington, MA (US); Kevin Tyler Sprott, Needham, MA (US); and Soumya Ray, Quincy, MA (US)
Assigned to Avilar Therapeutics, Inc., Waltham, MA (US)
Filed by Avilar Therapeutics, Inc., Waltham, MA (US)
Filed on Feb. 28, 2024, as Appl. No. 18/590,713.
Application 18/590,713 is a continuation of application No. 18/220,737, filed on Jul. 11, 2023, granted, now 12,091,402.
Application 18/220,737 is a continuation of application No. PCT/US2022/027513, filed on May 3, 2022.
Claims priority of provisional application 63/331,592, filed on Apr. 15, 2022.
Claims priority of provisional application 63/293,447, filed on Dec. 23, 2021.
Claims priority of provisional application 63/228,067, filed on Jul. 31, 2021.
Claims priority of provisional application 63/183,450, filed on May 3, 2021.
Prior Publication US 2024/0279209 A1, Aug. 22, 2024
Int. Cl. C07D 405/12 (2006.01); C07D 405/14 (2006.01); C07D 417/12 (2006.01); C07H 5/06 (2006.01); C07H 17/02 (2006.01)
CPC C07D 405/12 (2013.01) [C07D 405/14 (2013.01); C07D 417/12 (2013.01); C07H 5/06 (2013.01); C07H 17/02 (2013.01)] 11 Claims
 
1. A compound selected from:

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.